A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma

Trial Profile

A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs ENMD 2076 (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 05 Nov 2015 Results published in a CASI Pharmaceuticals media release.
    • 05 Nov 2015 According to a CASI Pharmaceuticals media release, data from this study will be presented at the 2015 Connective Tissue Oncology Society (CTOS) annual meeting 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top